Key Developments: Sequenom Inc (SQNM.OQ)
4.19USD
4:00pm EDT
$-0.13 (-3.01%)
$4.32
$4.32
$4.37
$4.17
393,032
509,795
$5.36
$2.65
Latest Key Developments (Source: Significant Developments)
Sequenom Inc Provides Update On Status Of Patent For Methods Of Detecting Fetal Aneuploidy
Sequenom Inc announced that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter. Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent. Full Article
Sequenom Inc Announces Leadership Appointments-DJ
Dow Jones reported that Sequenom, Inc. announced the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately. Additionally, Ronald Lindsay has been named as the Company's Executive Vice President, Strategic Planning. Harry F. Hixson, Jr. will continue to serve as Chairman and Chief Executive Officer. Full Article
Sequenom Inc Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy
Sequenom Inc announced that the U.S. Patent and Trademark Office will issue U.S. Patent No. 8,340,916 on December 25, 2012 with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent. Full Article
Sequenom Inc Announces Completion Of Offering Of $130 Million Of 5.00% Convertible Senior Notes
Sequenom Inc announced the completion of its offering of $130.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering, including $20.0 million aggregate principal amount of notes sold pursuant to the full exercise of an over-allotment option previously granted to the initial purchasers. Sequenom intends to use the net proceeds from this offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses. Full Article
Sequenom Inc Prices Offering Of $110 Million Of 5.00% Convertible Senior Notes Due 2017
Sequenom Inc announced the pricing of offering of $110.0 million aggregate principal amount of Convertible Senior Notes due 2017 in a private offering. The sale of the Convertible Notes is expected to close on September 17, 2012. Sequenom also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0 million aggregate principal amount of the Convertible Notes solely to cover over-allotments. Sequenom intends to use the net proceeds from this offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses. The Convertible Notes will be the senior, unsecured obligations of Sequenom. They will bear interest at a fixed rate of 5.00% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning April 1, 2013. Interest on the Convertible Notes will accrue from September 17, 2012. The Convertible Notes will mature on October 1, 2017, unless earlier converted, redeemed or repurchased. Full Article
Sequenom Inc Proposes Offering Of $100 Million Of Convertible Senior Notes
Sequenom Inc announced that it intends to offer, subject to market and other considerations, $100.0 million aggregate principal amount of Convertible Senior Notes due 2017 (the Convertible Notes) in a private offering. Sequenom also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0 million aggregate principal amount of the Convertible Notes solely to cover over-allotments, if any. Sequenom intends to use the net proceeds from the offering to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses. The Convertible Notes will be the senior, unsecured obligations of Sequenom and will accrue interest payable semiannually in arrears. The Convertible Notes will be convertible at any time prior to the third trading day immediately preceding the maturity date, at the option of the holders, into shares of Sequenom's common stock. The interest rate, conversion rate, conversion price and other terms of the Convertible Notes will be determined at the time of pricing of the offering. Full Article
Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
Sequenom, Inc. announced that it has filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit from the July 5, 2012 Preliminary Injunction Order of the U.S. District Court for the Northern District of California denying Sequenom's request for preliminary injunctive relief. Sequenom had previously requested that the district court enjoin Aria Diagnostics' (now Ariosa Diagnostics, Inc.) continued infringement of U.S. Patent No. 6,258,540 ("'540 patent"). Full Article
Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria Diagnostics
Sequenom, Inc. announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy, such as Aria's Harmony Prenatal Test, pending the ultimate resolution of the litigation. Sequenom's request for preliminary injunction follows the lawsuit filed on January 24, 2012, in the United States District Court for the Southern District of California, which alleges that Aria infringes U.S. Patent No. 6,258,540 (540 patent). Sequenom is requesting that the district court quickly intervene to stop Aria Diagnostics' continued infringement of the '540 patent. Sequenom Center for Molecular Medicine (Sequenom CMM) was the first to market a non-invasive prenatal diagnostics laboratory developed test (LDT) for chromosomal aneuploidy. Full Article
Sequenom, Inc. Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock
Sequenom, Inc. announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Sequenom at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering were approximately $62.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses. Jefferies & Company, Inc. acted as sole book-running manager for the offering, and Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. acted as co-managers for the offering. Full Article
Sequenom, Inc. Prices Public Offering of Common Stock
Sequenom, Inc announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering are expected to be $53.95 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Sequenom. Sequenom has granted the underwriters a 30-day option to purchase up to an aggregate of 1,950,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on or about January 25, 2012. Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses. Jefferies & Company, Inc. is acting as sole book-running manager for the offering, and Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. are acting as co-managers for the offering. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
